ozanimod vs tamuzimod
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline
ozanimod · Zeposia
Marketed by Bristol-Myers Squibb and partners
NCT02435992 · Phase 3 · completed
Randomized, quadruple-blinded, placebo-controlled, large adequately powered Phase 3 trial (n=1012) with a hard clinical/endoscopic remission endpoint that achieved statistical significance in the favorable direction at both induction and maintenance timepoints, satisfying the 'strong' definition.
Next expected readout: July 2032 · NCT05076175 (registry estimate)
Reported efficacy
Percentage of Participants in Clinical Remission at 10 Weeks; Percentage of Participants in Clinical Remission at 52 Weeks: Percentage of Participants in Clinical Remission at 10 Weeks (At 10 Weeks): RPC1063 Cohort 1(Induction Period) 18.4% vs Placebo Cohort 1 (Induction Period) 6.0% vs RPC1063 Cohort 2 (Induction Period) 21.0%; p=0.0001 (RPC1063 Cohort 1(Induction Period) vs Placebo Cohort 1 (Induction Period)) (met)
Result source: NCT02435992
tamuzimod
Developed by Eli Lilly and partners
NCT05156125 · Phase 2 · terminated
This was a randomized, quadruple-blind, placebo-controlled trial in 213 patients using clinical remission on the modified Mayo score, a validated disease-activity measure combining symptoms and endoscopy, as the primary endpoint. Both the 60 mg and 30 mg tamuzimod doses achieved significantly higher remission rates than placebo at week 13.
Reported efficacy
Clinical Remission at 13 Weeks (Day 1 of Induction treatment period to Week 13): Clinical Remission at 13 Weeks (Day 1 of Induction treatment period to Week 13): VTX002 60 mg Once Daily 19/68 (27.9%) | VTX002 30 mg Once Daily 17/71 (23.9%) vs Placebo Once Daily 8/70 (11.4%) (met)
Result source: NCT05156125
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ozanimod | tamuzimod |
|---|---|---|
| Clinical remission (induction) | 18.4% vs 6%+12.4 vs placeboNCT024359923 other results
| 27.9% vs 11.4%+16.5 vs placeboNCT051561251 other result
|
| Clinical remission (maintenance) | 37% vs 18.5%+18.5 vs placeboNCT024359922 other results
| —Not reported |
| Clinical response (induction) | 47.8% vs 25.9%+21.9 vs placeboNCT024359923 other results
| —Not reported |
| Endoscopic improvement (induction) | 27.3% vs 11.6%+15.7 vs placeboNCT024359923 other results
| —Not reported |
| Corticosteroid-free remission (maintenance) | 31.7% vs 16.7%+15 vs placeboNCT02435992 | —Not reported |
Clinical remission (induction)
- ozanimod
- 18.4% vs 6%+12.4 vs placeboNCT02435992
3 other results
- 21% vs 6% NCT02435992
- 16.4% vs 6.2% NCT01647516
- 13.8% vs 6.2% NCT01647516
- tamuzimod
- 27.9% vs 11.4%+16.5 vs placeboNCT05156125
1 other result
- 23.9% vs 11.4% NCT05156125
Clinical remission (maintenance)
- ozanimod
- 37% vs 18.5%+18.5 vs placeboNCT02435992
2 other results
- 20.9% vs 6.2% NCT01647516
- 26.2% vs 6.2% NCT01647516
- tamuzimod
- —Not reported
Clinical response (induction)
- ozanimod
- 47.8% vs 25.9%+21.9 vs placeboNCT02435992
3 other results
- 52.6% vs 25.9% NCT02435992
- 56.7% vs 36.9% NCT01647516
- 53.8% vs 36.9% NCT01647516
- tamuzimod
- —Not reported
Endoscopic improvement (induction)
- ozanimod
- 27.3% vs 11.6%+15.7 vs placeboNCT02435992
3 other results
- 27.2% vs 11.6% NCT02435992
- 34.3% vs 12.3% NCT01647516
- 27.7% vs 12.3% NCT01647516
- tamuzimod
- —Not reported
Corticosteroid-free remission (maintenance)
- ozanimod
- 31.7% vs 16.7%+15 vs placeboNCT02435992
- tamuzimod
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ozanimod: 4 of 4 rows · tamuzimod: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | ozanimod | tamuzimod |
|---|---|---|
| Dropout rate | —1mga NCT02435992 · Phase 3 · monotherapy show 15 more results—1mg NCT02435992 · Phase 3 · monotherapy —1mg NCT02435992 · Phase 3 · monotherapy —RPC1063 (Maintenance Period) NCT02435992 · Phase 3 · monotherapy 11.7%RPC1063 Cohort 2 (Induction Period NCT02435992 · Phase 3 · monotherapy 46.3%RPC01-202 Ozanimod Open Label NCT02531126 · Phase 3 · monotherapy 69.5%RPC01-3101 Ozanimod-Ozanimod NCT02531126 · Phase 3 · monotherapy —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 6%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg/1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 4.5%0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —Open-Label Treatment Period (OLP): NCT01647516 · Phase 2 · registry result, not featured evidence | 4.3%60 mg once dailya NCT05156125 · Phase 2 · monotherapy show 6 more results—60 mg once daily NCT05156125 · Phase 2 · monotherapy —60 mg once daily NCT05156125 · Phase 2 · monotherapy —60 mg once daily NCT05156125 · Phase 2 · monotherapy 4.1%30 mg once daily NCT05156125 · Phase 2 · monotherapy —30 mg once daily NCT05156125 · Phase 2 · monotherapy —30 mg once daily NCT05156125 · Phase 2 · monotherapy |
| Discontinued due to AEs | —1mga NCT02435992 · Phase 3 · monotherapy show 15 more results—1mg NCT02435992 · Phase 3 · monotherapy —1mg NCT02435992 · Phase 3 · monotherapy —RPC1063 (Maintenance Period) NCT02435992 · Phase 3 · monotherapy 3.3%RPC1063 Cohort 2 (Induction Period NCT02435992 · Phase 3 · monotherapy 7.4%RPC01-202 Ozanimod Open Label NCT02531126 · Phase 3 · monotherapy 6.1%RPC01-3101 Ozanimod-Ozanimod NCT02531126 · Phase 3 · monotherapy —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 0%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg/1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 3%0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —Open-Label Treatment Period (OLP): NCT01647516 · Phase 2 · registry result, not featured evidence | 2.9%60 mg once dailya NCT05156125 · Phase 2 · monotherapy show 6 more results—60 mg once daily NCT05156125 · Phase 2 · monotherapy —60 mg once daily NCT05156125 · Phase 2 · monotherapy —60 mg once daily NCT05156125 · Phase 2 · monotherapy 1.4%30 mg once daily NCT05156125 · Phase 2 · monotherapy —30 mg once daily NCT05156125 · Phase 2 · monotherapy —30 mg once daily NCT05156125 · Phase 2 · monotherapy |
| Serious AEs | 4%1mga NCT02435992 · Phase 3 · monotherapy show 15 more results6.3%1mg NCT02435992 · Phase 3 · monotherapy 5.2%1mg NCT02435992 · Phase 3 · monotherapy —RPC1063 (Maintenance Period) NCT02435992 · Phase 3 · monotherapy —RPC1063 Cohort 2 (Induction Period NCT02435992 · Phase 3 · monotherapy 14.8%RPC01-202 Ozanimod Open Label NCT02531126 · Phase 3 · monotherapy 17.2%RPC01-3101 Ozanimod-Ozanimod NCT02531126 · Phase 3 · monotherapy 3%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 2.4%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 18.6%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 1.5%0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence 0%0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence 25%0.5 mg/1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence 9.1%Open-Label Treatment Period (OLP): NCT01647516 · Phase 2 · registry result, not featured evidence | —60 mg once dailya NCT05156125 · Phase 2 · monotherapy show 6 more results4.3%60 mg once daily NCT05156125 · Phase 2 · monotherapy 0%60 mg once daily NCT05156125 · Phase 2 · monotherapy 4.2%60 mg once daily NCT05156125 · Phase 2 · monotherapy —30 mg once daily NCT05156125 · Phase 2 · monotherapy 2.7%30 mg once daily NCT05156125 · Phase 2 · monotherapy 5.4%30 mg once daily NCT05156125 · Phase 2 · monotherapy |
| Most frequent reported AEs | show 11 more resultscovid-19 25.9% (placebo 16.8%) lymphopenia 16.7% (placebo 17.3%) leukopenia 7.4% (placebo 4.1%) NCT02531126 · Phase 3 · monotherapy lymphopenia 16.3% (placebo 17.3%) covid-19 11.3% (placebo 16.8%) lymphocyte count decreased 10.8% (placebo 12.8%) NCT02531126 · Phase 3 · monotherapy 1 mg alanine aminotransferase increased 3% (placebo 0%) headache 3% (placebo 4.6%) anaemia 1.5% (placebo 6.2%) NCT01647516 · Phase 2 · registry result, not featured evidence 1 mg alanine aminotransferase increased 2.4% (placebo 0%) colitis ulcerative 2.4% (placebo 1.5%) anaemia 0% (placebo 6.2%) NCT01647516 · Phase 2 · registry result, not featured evidence 1 mg hypertension 11.9% (placebo 0%) gamma-glutamyltransferase increased 8.5% (placebo 0%) upper respiratory tract infection 8.5% (placebo 3.1%) NCT01647516 · Phase 2 · registry result, not featured evidence 0.5 mg anaemia 6.2% (placebo 6.2%) colitis ulcerative 3.1% (placebo 1.5%) back pain 1.5% (placebo 1.5%) NCT01647516 · Phase 2 · registry result, not featured evidence 0.5 mg alanine aminotransferase increased 2.8% (placebo 0%) nasopharyngitis 2.8% (placebo 0%) anaemia 0% (placebo 6.2%) NCT01647516 · Phase 2 · registry result, not featured evidence 0.5 mg/1 mg anaemia 5.4% (placebo 6.2%) gamma-glutamyltransferase increased 5.4% (placebo 0%) lymphocyte count decreased 5.4% (placebo 0%) NCT01647516 · Phase 2 · registry result, not featured evidence anaemia 7.3% (placebo 6.2%) colitis ulcerative 7.3% (placebo 1.5%) bronchitis 5.5% (placebo 0%) NCT01647516 · Phase 2 · registry result, not featured evidence | 60 mg once dailya upper respiratory tract infection 8.6% (placebo 1.4%) headache 5.7% (placebo 2.9%) anaemia 2.9% (placebo 8.6%) NCT05156125 · Phase 2 · monotherapy show 4 more results60 mg once daily alanine aminotransferase increased 6.1% (placebo 1.4%) aspartate animotransferase increased 6.1% (placebo 0%) gamma-glutamyltransferase increased 6.1% (placebo 1.4%) NCT05156125 · Phase 2 · monotherapy 60 mg once daily lymphopenia 28.9% (placebo 0%) nasopharyngitis 7.4% (placebo 4.3%) upper respiratory tract infection 6.3% (placebo 1.4%) NCT05156125 · Phase 2 · monotherapy 30 mg once daily headache 6.8% (placebo 2.9%) anaemia 5.5% (placebo 8.6%) lymphopenia 1.4% (placebo 0%) NCT05156125 · Phase 2 · monotherapy 30 mg once daily gamma-glutamyltransferase increased 10.8% (placebo 1.4%) alanine aminotransferase increased 5.4% (placebo 1.4%) arthralgia 5.4% (placebo 0%) NCT05156125 · Phase 2 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ozanimod
show 6 more results
show 6 more results
show 2 more results
show 4 more results
show 4 more results
show 9 more results
show 4 more results
show 9 more results
show 9 more results
show 6 more results
+ 5 further endpoints in the CSV export.
tamuzimod
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ozanimod's landscape · tamuzimod's landscape